How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Abstract: It is challenging to extend the support region of state-of-the-art local edge-preserving filtering approaches to the entire input image on account of huge memory cost and heavy computational ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

We recently published 10 Best Biotech Stocks to Buy Under $10. Recursion Pharmaceuticals, Inc. is placed eighth among them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage ...

Abstract: Recursion is a fundamental computation mechanism which has been incorporated into the SQL language. This work focuses on the optimization of linear recursive queries in SQL. Query ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...